Smith & Nephew (LON:SN) Earns “Buy” Rating from Jefferies Financial Group

Smith & Nephew (LON:SN – Get Free Report)‘s stock had its “buy” rating reaffirmed by research analysts at Jefferies Financial Group in a research note issued on Friday, Digital Look reports. They currently have a GBX 1,500 price target on the stock. Jefferies Financial Group’s price target indicates a potential upside of 42.59% from the company’s previous close.

A number of other research analysts have also weighed in on SN. Berenberg Bank reduced their target price on Smith & Nephew from GBX 1,300 to GBX 1,250 and set a “hold” rating for the company in a report on Friday, August 14th. Deutsche Bank Aktiengesellschaft restated a “hold” rating and issued a GBX 1,400 price objective on shares of Smith & Nephew in a research report on Thursday, July 30th. JPMorgan Chase & Co. reduced their price objective on shares of Smith & Nephew from GBX 1,438 to GBX 1,290 and set a “neutral” rating for the company in a research note on Thursday, August 6th. Citigroup lowered shares of Smith & Nephew to a “buy” rating in a report on Friday, July 10th. Finally, Royal Bank Of Canada lowered their target price on shares of Smith & Nephew from GBX 1,350 to GBX 1,250 and set a “sector perform” rating on the stock in a research note on Thursday, August 6th. Three equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat.com, Smith & Nephew currently has a consensus rating of “Hold” and a consensus price target of GBX 1,310.

Get Smith & Nephew alerts:

Check Out Our Latest Research Report on Smith & Nephew

Smith & Nephew Stock Performance

Shares of LON SN opened at GBX 1,052 on Friday. The company has a debt-to-equity ratio of 73.07, a quick ratio of 0.84 and a current ratio of 2.14. The stock has a market capitalization of £11.53 billion, a PE ratio of 37.88, a PEG ratio of 0.46 and a beta of 0.69. The company has a fifty day moving average of GBX 1,118.14 and a two-hundred day moving average of GBX 1,169.82.

About Smith & Nephew

(Get Free Report)

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.

Featured Articles

• Five stocks we like better than Smith & Nephew
• The Path to $230 Billion: Broadcom Outlines the Next Phase of Its AI Growth Story
• NVIDIA’s Hugging Face Deal Raises a Bigger Question About Its AI Moat Now
• Dropping the Dough: Yum! Brands Strategically Trims the Fat
• These 3 Stock Charts Just Flashed the Dreaded Death Cross Pattern

Receive News & Ratings for Smith & Nephew Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew and related companies with MarketBeat.com's FREE daily email newsletter.